Vitamin D receptor regulates TGF-β signalling in systemic sclerosis

Annals of the Rheumatic Diseases

Volumn 74, Issue 3, 2015, Pages

  Zerr, Pawel ^a   Vollath, Stefan ^a   Palumbo Zerr, Katrin ^a   Tomcik, Michal ^a,b   Huang, Jingang ^a   Distler, Alfiya ^a   Beyer, Christian ^a   Dees, Clara ^a   Gela, Kolja ^a   Distler, Oliver ^c   Schett, Georg ^a   Distler, Jörg H W ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; PARICALCITOL; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; VITAMIN D RECEPTOR; BLEOMYCIN; CALCITRIOL RECEPTOR; ERGOCALCIFEROL; SMAD PROTEIN; SMALL INTERFERING RNA; VDR PROTEIN, HUMAN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; COLLAGEN SYNTHESIS; COMPLEX FORMATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SKIN FIBROBLAST; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; TRANSCRIPTION REGULATION; AGONISTS; ANIMAL; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; FEMALE; FIBROSIS; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; SKIN; YOUNG ADULT;

ADULT; AGED; ANIMALS; BLEOMYCIN; DISEASE MODELS, ANIMAL; ERGOCALCIFEROLS; FEMALE; FIBROBLASTS; FIBROSIS; HUMANS; MALE; MICE; MIDDLE AGED; RECEPTORS, CALCITRIOL; RNA, SMALL INTERFERING; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; SKIN; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA; YOUNG ADULT;

EID: 84928169015     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204378     Document Type: Article

References (51)

1. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009; 360: 1989-2003.
2. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007; 117: 557-67.
3. Beyer C, Distler O, Distler JH. Innovative antifibrotic therapies in systemic sclerosis. Curr Opin Rheumatol 2012; 24: 274-80.
4. Kowal-Bielecka O, Landewe R, Avouac J, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009; 68: 620-8.
5. Haroon M, Fitzgerald O. Vitamin D and its emerging role in immunopathology. Clin Rheumatol 2012; 31: 199-202.
6. Cutolo M. Further emergent evidence for the vitamin D endocrine system involvement in autoimmune rheumatic disease risk and prognosis. Ann Rheum Dis 2013; 72: 473-5.
7. Messa P, Alfieri C, Rastaldi MP. Recent insights into vitamin D and its receptor. J Nephrol 2011; 24(Suppl 18): S30-37.
8. Yee YK, Chintalacharuvu SR, Lu J, et al. Vitamin D receptor modulators for inflammation and cancer. Mini Rev Med Chem 2005; 5: 761-78.
9. Arnson Y, Amital H, Agmon-Levin N, et al. Serum 25-OH vitamin D concentrations are linked with various clinical aspects in patients with systemic sclerosis: a retrospective cohort study and review of the literature. Autoimmun Rev 2011; 10: 490-4.
10. Belloli L, Ughi N, Marasini B. Vitamin D in systemic sclerosis. Clin Rheumatol 2011; 30: 145-6.
11. Calzolari G, Data V, Carignola R, et al. Hypovitaminosis D in systemic sclerosis. J Rheumatol 2009; 36: 2844; author reply 2845.
12. Caramaschi P, Dalla Gassa A, Ruzzenente O, et al. Very low levels of vitamin D in systemic sclerosis patients. Clin Rheumatol 2010; 29: 1419-25.
13. Gambichler T, Chrobok I, Hoxtermann S, et al. Significantly decreased serum 25-hydroxyvitamin d levels in a large german systemic sclerosis cohort. J Rheumatol 2011; 38: 2492-3; author reply 2494.
14. Rios Fernandez R, Fernandez Roldan C, Callejas Rubio JL, et al. Vitamin D deficiency in a cohort of patients with systemic scleroderma from the south of Spain. J Rheumatol 2010; 37: 1355; author reply 1356.
15. Rios-Fernandez R, Callejas-Rubio JL, Fernandez-Roldan C, et al. Bone mass and vitamin D in patients with systemic sclerosis from two Spanish regions. Clin Exp Rheumatol 2012; 30: 905-11.
16. Vacca A, Cormier C, Piras M, et al. Vitamin D deficiency and insufficiency in 2 independent cohorts of patients with systemic sclerosis. J Rheumatol 2009; 36: 1924-9.
17. Szyszka P, Zmijewski MA, Slominski AT. New vitamin D analogs as potential therapeutics in melanoma. Expert Rev Anticancer Ther 2012; 12: 585-99.
18. Slatopolsky E, Dusso A, Brown A. New analogs of vitamin D3. Kidney Int Suppl 1999; 73: S46-51.
19. Sprague SM, Llach F, Amdahl M, et al. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003; 63: 1483-90.
20. Akhmetshina A, Dees C, Pileckyte M, et al. Rho-associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts. Arthritis Rheum 2008; 58: 2553-64.
21. Kronke G, Reich N, Scholtysek C, et al. The 12/15-lipoxygenase pathway counteracts fibroblast activation and experimental fibrosis. Ann Rheum Dis 2012; 71: 1081-7.
22. Akhmetshina A, Beer J, Zwerina K, et al. Decreased lymphatic vessel counts in patients with systemic sclerosis: association with fingertip ulcers. Arthritis Rheum 2010; 62: 1513-22.
23. Beyer C, Schramm A, Akhmetshina A, et al. beta-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis. Ann Rheum Dis 2012; 71: 761-7.
24. Dees C, Akhmetshina A, Zerr P, et al. Platelet-derived serotonin links vascular disease and tissue fibrosis. J Exp Med 2011; 208: 961-72.
25. Horn A, Palumbo K, Cordazzo C, et al. Hedgehog signaling controls fibroblast activation and tissue fibrosis in systemic sclerosis. Arthritis Rheum 2012; 64: 2724-33.
26. Akhmetshina A, Palumbo K, Dees C, et al. Activation of canonical Wnt signalling is required for TGF-beta-mediated fibrosis. Nat Commun 2012; 3: 735.
27. Dees C, Tomcik M, Palumbo-Zerr K, et al. JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor beta in systemic sclerosis. Arthritis Rheum 2012; 64: 3006-15.
28. Dees C, Schlottmann I, Funke R, et al. The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis. Ann Rheum Dis 2014; 73: 1232-9.
29. Zerr P, Palumbo-Zerr K, Distler A, et al. Inhibition of hedgehog signaling for the treatment of murine sclerodermatous chronic graft-versus-host disease. Blood 2012; 120: 2909-17.
30. Beyer C, Reich N, Schindler SC, et al. Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis. Ann Rheum Dis 2012; 71: 1019-26.
31. Dees C, Tomcik M, Zerr P, et al. Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis. Ann Rheum Dis 2011; 70: 1304-10.
32. Palumbo K, Zerr P, Tomcik M, et al. The transcription factor JunD mediates transforming growth factor {beta}-induced fibroblast activation and fibrosis in systemic sclerosis. Ann Rheum Dis 2011; 70: 1320-6.
33. Li YC, Pirro AE, Amling M, et al. Targeted ablation of the vitamin D receptor: an animal model of vitamin D-dependent rickets type II with alopecia. Proc Natl Acad Sci USA 1997; 94: 9831-5.
34. Beyer C, Reichert H, Akan H, et al. Blockade of canonical Wnt signalling ameliorates experimental dermal fibrosis. Ann Rheum Dis 2013; 72: 1255-8.
35. Beyer C, Skapenko A, Distler A, et al. Activation of pregnane X receptor inhibits experimental dermal fibrosis. Ann Rheum Dis 2013; 72: 621-5.
36. Tomcik M, Zerr P, Pitkowski J, et al. Heat shock protein 90 (Hsp90) inhibition targets canonical TGF-beta signalling to prevent fibrosis. Ann Rheum Dis 2014; 73: 1215-22.
37. Khodzhigorova A, Distler A, Lang V, et al. Inhibition of sumoylation prevents experimental fibrosis. Ann Rheum Dis 2012; 71: 1904-8.
38. Bergmann C, Akhmetshina A, Dees C, et al. Inhibition of glycogen synthase kinase 3beta induces dermal fibrosis by activation of the canonical Wnt pathway. Ann Rheum Dis 2011; 70: 2191-8.
39. Marquart S, Zerr P, Akhmetshina A, et al. Inactivation of the cannabinoid receptor CB1 prevents leukocyte infiltration and experimental fibrosis. Arthritis Rheum 2010; 62: 3467-76.
40. Reich N, Tomcik M, Zerr P, et al. Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis. Ann Rheum Dis 2012; 71: 737-45.
41. Kramer M, Dees C, Huang J, et al. Inhibition of H3K27 histone trimethylation activates fibroblasts and induces fibrosis. Ann Rheum Dis 2013; 72: 614-20.
42. Weingartner S, Zerr P, Tomcik M, et al. Pomalidomide is effective for prevention and treatment of experimental skin fibrosis. Ann Rheum Dis 2012; 71: 1895-9.
43. LeRoy EC. Increased collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblast. J Clin Invest 1974; 54: 880-9.
44. Avouac J, Koumakis E, Toth E, et al. Increased risk of osteoporosis and fracture in women with systemic sclerosis: a comparative study with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 1871-8.
45. Shinjo SK, Bonfa E, de Falco Caparbo V, et al. Low bone mass in juvenile onset sclerosis systemic: the possible role for 25-hydroxyvitamin D insufficiency. Rheumatol Int 2011; 31: 1075-80.
46. Beyer C, Schett G, Distler O, et al. Animal models of systemic sclerosis: prospects and limitations. Arthritis Rheum 2010; 62: 2831-44.
47. Ito I, Waku T, Aoki M, et al. A nonclassical vitamin D receptor pathway suppresses renal fibrosis. J Clin Invest 2013; 123: 4579-94.
48. Xiong M, Gong J, Liu Y, et al. Loss of vitamin D receptor in chronic kidney disease: a potential mechanism linking inflammation to epithelial-to-mesenchymal transition. Am J Physiol Renal Physiol 2012; 303: F1107-15.
49. Zhang Y, Kong J, Deb DK, et al. Vitamin D receptor attenuates renal fibrosis by suppressing the renin-angiotensin system. J Am Soc Nephrol 2010; 21: 966-73.
50. Ding N, Yu RT, Subramaniam N, et al. A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. Cell 2013; 153: 601-13.
51. Slominski A, Janjetovic Z, Tuckey RC, et al. 20S-hydroxyvitamin D3, noncalcemic product of CYP11A1 action on vitamin D3, exhibits potent antifibrogenic activity in vivo. J Clin Endocrinol Metab 2013; 98: E298-303.